SOURCE: CLX Investment Company, Inc.

August 16, 2007 09:47 ET

CLX Investment Company Announces Form 4 Filings for Consultant CEO and Director

MURRIETA, CA--(Marketwire - August 16, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN) today announced that Consultant CEO Steven R. Peacock and Director James Bickel have filed Form 4 Statement of Change in Beneficial Ownership of Securities documents with the Securities and Exchange Commission reporting the acquisition of additional shares of common stock.

Mr. Peacock's Form 4 reports the acquisition of 10 million shares of CLX common stock, bringing the total number of common shares that Mr. Peacock owns to 13 million shares. Mr. Bickel's Form 4 also reports the acquisition of 10 million shares of CLX common stock, bringing the total number of common shares that Mr. Bickel owns to 10,250,000 shares of CLX common stock.

The 10,000,000 shares acquired by both Mr. Peacock and Mr. Bickel are in the form of restricted common stock and were received as part of a stock purchase agreement under which CLX purchased an additional 10% of the issued and outstanding shares of Zonda, Incorporated. Before the stock purchase, Mr. Peacock and Mr. Bickel each owned a 5% interest in Zonda, Inc.

"The CLX Board of Directors determined that as part of the company's strategy to deliver value to shareholders, CLX should acquire an additional equity in Zonda, Inc.," stated Chairman Robert McCoy. "The acquisition of the additional 10% will provide a more advantageous position for CLX as a shareholder of Zonda, and by purchasing this additional ownership with restricted CLX common stock, rather than with cash or free-trading stock, the immediate impact on the company is minimal."

Mr. Peacock commented, "Because I believe in CLX's strategy to deliver long-term value to shareholders, I am quite satisfied to receive restricted CLX common stock in exchange for my shares of Zonda, Incorporated."

Zonda, Incorporated is a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

Zonda's strong intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company's first medical test for Chlamydia is currently sold throughout Europe under the HandiLab brand and is expected to launch in the U.S. at the end of the first quarter 2008. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Investment Company

CLX Investment Company ( holds a 41% equity interest in Zonda, Inc. ( CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact